Whitney H Beeler1, Emily L Bellile2, Keith A Casper3, Elizabeth Jaworski1, Nicholas J Burger3, Kelly M Malloy3, Matthew E Spector3, Andrew G Shuman4, Andrew Rosko3, Chaz L Stucken3, Steven B Chinn3, Aleksandar F Dragovic1, Christina H Chapman5, Dawn Owen1, Shruti Jolly1, Carol R Bradford3, Mark E P Prince4, Francis P Worden6, Reshma Jagsi1, Michelle L Mierzwa1, Paul L Swiecicki7. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States. 2. Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States. 3. Department of Otolaryngology, University of Michigan, Ann Arbor, MI, United States. 4. Department of Otolaryngology, University of Michigan, Ann Arbor, MI, United States; Department of Otolaryngology, Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI, United States. 5. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States; Department of Radiation Oncology, Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI, United States. 6. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. 7. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States; Department of Internal Medicine, Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI, United States. Electronic address: pswiecic@med.umich.edu.
Abstract
OBJECTIVES: Financial toxicity (FT) is a significant barrier to high-quality cancer care, and patients with head and neck cancer (HNCA) are particularly vulnerable given their need for intensive support, daily radiotherapy (RT), and management of long-term physical, functional, and psychosocial morbidities following treatment. We aim to identify predictors of FT and adverse consequences in HNCA following RT. MATERIALS AND METHODS: We performed a prospective survey study of patients with HNCA seen in follow-up at an academic comprehensive cancer center (CCC) or Veterans Affairs hospital between 05/2016 and 06/2018. Surveys included validated patient-reported functional outcomes and the COST measure, a validated instrument for measuring FT. RESULTS: The response rate was 86% (n = 63). Younger age and lower median household income by county were associated with lower COST scores (i.e., worse FT) on multivariable analysis (p = .045 and p = .016, respectively). Patients with worse FT were more likely to skip clinic visits (RR (95% CI) 2.13 (1.23-3.67), p = .007), be noncompliant with recommended supplements or medications (1.24 (1.03-1.48), p = .02), and require supportive infusions (1.10 (1.02-1.20), p = .02). At the CCC, patients with worse FT were more likely to require feeding tubes (1.62 (1.14-2.31), p = .007). Overall, 36% reported that costs were higher than expected, 48% were worried about paying for treatment, and 33% reported at least a moderate financial burden from treatment. CONCLUSION: HNCA patients experience substantial FT from their diagnosis and/or therapy, with potential implications for medical compliance, QOL, and survivorship care. Published by Elsevier Ltd.
OBJECTIVES:Financial toxicity (FT) is a significant barrier to high-quality cancer care, and patients with head and neck cancer (HNCA) are particularly vulnerable given their need for intensive support, daily radiotherapy (RT), and management of long-term physical, functional, and psychosocial morbidities following treatment. We aim to identify predictors of FT and adverse consequences in HNCA following RT. MATERIALS AND METHODS: We performed a prospective survey study of patients with HNCA seen in follow-up at an academic comprehensive cancer center (CCC) or Veterans Affairs hospital between 05/2016 and 06/2018. Surveys included validated patient-reported functional outcomes and the COST measure, a validated instrument for measuring FT. RESULTS: The response rate was 86% (n = 63). Younger age and lower median household income by county were associated with lower COST scores (i.e., worse FT) on multivariable analysis (p = .045 and p = .016, respectively). Patients with worse FT were more likely to skip clinic visits (RR (95% CI) 2.13 (1.23-3.67), p = .007), be noncompliant with recommended supplements or medications (1.24 (1.03-1.48), p = .02), and require supportive infusions (1.10 (1.02-1.20), p = .02). At the CCC, patients with worse FT were more likely to require feeding tubes (1.62 (1.14-2.31), p = .007). Overall, 36% reported that costs were higher than expected, 48% were worried about paying for treatment, and 33% reported at least a moderate financial burden from treatment. CONCLUSION:HNCApatients experience substantial FT from their diagnosis and/or therapy, with potential implications for medical compliance, QOL, and survivorship care. Published by Elsevier Ltd.
Entities:
Keywords:
Head and neck neoplasms; Health care costs; Health expenditures; Quality of life
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Jonas A de Souza; Bonnie J Yap; Fay J Hlubocky; Kristen Wroblewski; Mark J Ratain; David Cella; Christopher K Daugherty Journal: Cancer Date: 2014-06-20 Impact factor: 6.860
Authors: Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky Journal: J Clin Oncol Date: 2015-06-22 Impact factor: 44.544
Authors: Joshua R Niska; Michele Y Halyard; Angelina D Tan; Pamela J Atherton; Samir H Patel; Jeff A Sloan Journal: Qual Life Res Date: 2017-02-28 Impact factor: 4.147
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Reshma Jagsi; Paul H Abrahamse; Kamaria L Lee; Lauren P Wallner; Nancy K Janz; Ann S Hamilton; Kevin C Ward; Monica Morrow; Allison W Kurian; Christopher R Friese; Sarah T Hawley; Steven J Katz Journal: Cancer Date: 2017-10-09 Impact factor: 6.860
Authors: Scott D Ramsey; Aasthaa Bansal; Catherine R Fedorenko; David K Blough; Karen A Overstreet; Veena Shankaran; Polly Newcomb Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Elizabeth A Repasky; Anurag K Singh Journal: Oral Oncol Date: 2020-06-16 Impact factor: 5.337
Authors: Debbie W Chen; David Reyes-Gastelum; Christine M Veenstra; Ann S Hamilton; Mousumi Banerjee; Megan R Haymart Journal: Thyroid Date: 2020-09-22 Impact factor: 6.568
Authors: Grace L Smith; Shuangshuang Fu; Matthew S Ning; Diem-Khanh Nguyen; Paul M Busse; Robert L Foote; Adam S Garden; Gary B Gunn; Clifton D Fuller; William H Morrison; Gregory M Chronowski; Shalin J Shah; Lauren L Mayo; Jack Phan; Jay P Reddy; James W Snider; Samir H Patel; Sanford R Katz; Alexander Lin; Nasiruddin Mohammed; Roi Dagan; Nancy Y Lee; David I Rosenthal; Steven J Frank Journal: Int J Part Ther Date: 2021-06-25